RINVOQ® is an oral selective and reversible JAK inhibitor indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1
Help your patients disrupt the itch & rash of moderate to severe AD.
Browse our educational resources below to learn more about RINVOQ.
RINVOQ: YOUR RAPID INTRODUCTION
Learn why RINVOQ may be an appropriate treatment option for your moderate to severe AD patients.
[project # ALL-RNQD-200072]
RINVOQ EFFICACY & SAFETY SUMMARY
Download a snapshot of RINVOQ's key efficacy and safety results from the Phase 3 trials.
[project # ALL-RNQD-200071]
RINVOQ INITIATION GUIDE
Start your patients on RINVOQ with this practical guide for dosing, initiation, and monitoring.
[project # ALL-RNQD-200070]
KEY PUBLICATION: MEASURE UP 1 & 2 CLINICAL TRIAL
Download the journal reprint of the MEASURE UP 1 & 2 clinical trial.
[Article, journal]
KEY PUBLICATION: AD UP CLINICAL TRIAL
Download the journal reprint of the AD UP clinical trial.
[Article, journal]
KEY PUBLICATION: HEADS UP CLINICAL TRIAL
Download the journal reprint of the HEADS UP clinical trial.
[Article, journal]
[Affiliates to work with local legal and regulatory teams to ensure appropriate use of any tools and whether they are subject to medical device regulations]
[Affiliates to work with local legal and regulatory teams to ensure appropriate use of any tools and whether they are subject to medical device regulations]
[Affiliates to work with local legal and regulatory teams to ensure appropriate use of any tools and whether they are subject to medical device regulations]
Provides support for your patients to stay on track with their prescribed treatment plan. The [insert local patient support program name] program is tailored to your patients’ individual needs.
Patients enrolled in [insert local patient support program name] will have access to a range of resources to support them throughout their treatment experience.
Visit [insert local patient support program name] to find out more about patient support services.
Help your patients to self-assess and monitor the severity of their eczema.
[Self-assessment tools will not be developed at a global level; relevant tools that are developed and approved locally can be linked to from here if compliant with Local MedReg guidelines]
[LOCAL AFFILIATES TO INSERT PREFERRED EVENT]
Subhead
Date/Location
[LOCAL AFFILIATES TO INSERT PREFERRED EVENT]
Subhead
Date/Location
[LOCAL AFFILIATES TO INSERT PREFERRED EVENT]
Subhead
Date/Location
FIND OUT MORE ABOUT RINVOQ
REFERENCES
- RINVOQ® (upadacitinib) Summary of Product Characteristics. AbbVie Deutschland GmbH & Co. KG: June 2022.